• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Exploring factors associated with bleeding events after open heart surgery in patients on dialysis - effects of the presence or absence of warfarin therapy.探索透析患者心脏直视手术后出血事件的相关因素——华法林治疗与否的影响
J Pharm Health Care Sci. 2024 Jul 12;10(1):38. doi: 10.1186/s40780-024-00353-x.
2
D-dimer to guide the intensity of anticoagulation in Chinese patients after mechanical heart valve replacement: a randomized controlled trial.D-二聚体指导机械心脏瓣膜置换术后中国患者抗凝强度的随机对照试验。
J Thromb Haemost. 2017 Oct;15(10):1934-1941. doi: 10.1111/jth.13782. Epub 2017 Sep 20.
3
[Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].[全膝关节置换术后低分子肝素与华法林联合抗凝治疗的并发症及风险——我们的经验]
Acta Chir Orthop Traumatol Cech. 2004;71(4):237-44.
4
Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?生物人工主动脉瓣置换术后早期使用华法林进行抗凝治疗是否必要?
J Thorac Cardiovasc Surg. 2005 May;129(5):1024-31. doi: 10.1016/j.jtcvs.2004.11.028.
5
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.随机对照试验比较高剂量与低剂量低分子肝素在需要侵入性机械通气的严重 COVID-19 肺炎和凝血病住院患者中的疗效和安全性 (COVID-19 HD):研究方案的结构化总结。
Trials. 2020 Jun 26;21(1):574. doi: 10.1186/s13063-020-04475-z.
6
7
Mitral valve repair and bioprosthetic replacement without postoperative anticoagulation does not increase the risk of stroke or mortality.二尖瓣修复和生物瓣置换术后不进行抗凝治疗并不会增加中风或死亡的风险。
Eur J Cardiothorac Surg. 2013 Jul;44(1):24-31. doi: 10.1093/ejcts/ezs626. Epub 2013 Jan 4.
8
Variation in Warfarin Use at Hospital Discharge After Isolated Bioprosthetic Mitral Valve Replacement: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database.孤立性生物二尖瓣置换术后出院时华法林使用的变化:胸外科医师学会成人心脏外科学数据库分析。
Chest. 2016 Sep;150(3):597-605. doi: 10.1016/j.chest.2016.04.015. Epub 2016 Apr 29.
9
Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.窦性心律心力衰竭患者的抗血小板治疗与抗凝治疗对比
Cochrane Database Syst Rev. 2016 Sep 15;9(9):CD003333. doi: 10.1002/14651858.CD003333.pub3.
10
Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias.心律失常成人患者行导管消融术时,中断与不中断抗凝治疗的比较。
Cochrane Database Syst Rev. 2021 Oct 21;10(10):CD013504. doi: 10.1002/14651858.CD013504.pub2.

本文引用的文献

1
Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. frail 老年房颤患者由维生素 K 拮抗剂转换为非维生素 K 拮抗剂口服抗凝剂的安全性:FRAIL-AF 随机对照试验结果。
Circulation. 2024 Jan 23;149(4):279-289. doi: 10.1161/CIRCULATIONAHA.123.066485. Epub 2023 Aug 27.
2
JCS/JSCS/JATS/JSVS 2020 Guidelines on the Management of Valvular Heart Disease.JCS/JSCS/JATS/JSVS 2020年心脏瓣膜病管理指南
Circ J. 2020 Oct 23;84(11):2037-2119. doi: 10.1253/circj.CJ-20-0135. Epub 2020 Sep 11.
3
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease.《日本循环学会(JCS)2020年冠状动脉疾病患者抗栓治疗指南重点更新》
Circ J. 2020 Apr 24;84(5):831-865. doi: 10.1253/circj.CJ-19-1109. Epub 2020 Mar 13.
4
Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) - 1-Year Follow-up Results of a Postmarketing Observational Study.普拉格雷用于长期临床实践中的日本缺血性心脏病患者(PRASFIT-实践 II)- 上市后观察研究的 1 年随访结果。
Circ J. 2019 Dec 25;84(1):101-108. doi: 10.1253/circj.CJ-19-0645. Epub 2019 Nov 21.
5
Cardiovascular Event Rates Among Hemodialysis Patients Across Geographical Regions-A Snapshot From The Dialysis Outcomes and Practice Patterns Study (DOPPS).不同地理区域血液透析患者的心血管事件发生率——透析结果与实践模式研究(DOPPS)的简要情况
Kidney Int Rep. 2019 Mar 28;4(6):864-872. doi: 10.1016/j.ekir.2019.03.016. eCollection 2019 Jun.
6
Warfarin and the Risk of Death, Stroke, and Major Bleeding in Patients With Atrial Fibrillation Receiving Hemodialysis: A Systematic Review and Meta-Analysis.华法林与接受血液透析的心房颤动患者的死亡、中风及大出血风险:一项系统评价与荟萃分析
Front Pharmacol. 2018 Nov 6;9:1218. doi: 10.3389/fphar.2018.01218. eCollection 2018.
7
Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis.碳酸镧对开始血液透析后冠状动脉钙化和心脏异常的影响。
Calcif Tissue Int. 2018 Mar;102(3):310-320. doi: 10.1007/s00223-017-0347-3. Epub 2017 Oct 20.
8
Relationship between cardiac calcification and left ventricular hypertrophy in patients with chronic kidney disease at hemodialysis initiation.血液透析起始时慢性肾脏病患者心脏钙化与左心室肥厚的关系
Heart Vessels. 2017 Sep;32(9):1109-1116. doi: 10.1007/s00380-017-0969-4. Epub 2017 Mar 21.
9
Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study.普拉格雷用于日本急性冠状动脉综合征患者的短期临床实践(PRASFIT-实践I):一项上市后观察性研究。
Cardiovasc Interv Ther. 2018 Apr;33(2):135-145. doi: 10.1007/s12928-017-0459-8. Epub 2017 Feb 17.
10
Cardiothoracic Ratio and All-Cause Mortality and Cardiovascular Disease Events in Hemodialysis Patients: The Q-Cohort Study.心胸比与血液透析患者全因死亡率和心血管疾病事件:Q 队列研究。
Am J Kidney Dis. 2017 Jul;70(1):84-92. doi: 10.1053/j.ajkd.2016.11.026. Epub 2017 Feb 10.

探索透析患者心脏直视手术后出血事件的相关因素——华法林治疗与否的影响

Exploring factors associated with bleeding events after open heart surgery in patients on dialysis - effects of the presence or absence of warfarin therapy.

作者信息

Suzuki Masanori, Hasegawa Yuki, Tanabe Hiroaki, Koinuma Masayoshi, Funakoshi Ryohkan

机构信息

Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo, Japan.

Department of Pharmacy, Kameda Medical Center, Chiba, Japan.

出版信息

J Pharm Health Care Sci. 2024 Jul 12;10(1):38. doi: 10.1186/s40780-024-00353-x.

DOI:10.1186/s40780-024-00353-x
PMID:38997775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11241945/
Abstract

BACKGROUND

Perioperative management of patients on dialysis is critical for controlling bleeding and thrombotic risk, in addition to infection control. Postoperative anticoagulation is often difficult to control, and different institutions have different policies. Therefore, in this study, we aimed to investigate factors associated with postoperative bleeding events and whether warfarin (WF) therapy affects the incidence of postoperative bleeding events, total mortality, and stroke.

METHODS

Patients who were admitted to the cardiovascular surgery department and underwent valve replacement or plasty were included, and those who underwent mechanical valve introduction were excluded. Thirty-nine patients were included in the study. The primary endpoint was to identify factors associated with the composite endpoint of postoperative bleeding events, and the secondary endpoint was to determine the effect size of WF therapy on postoperative bleeding events, all-cause mortality, and stroke and the strength of association between the crossed endpoints. The strength of the association between the crossed items was examined.

RESULTS

Low body weight (p = 0.038) was identified as a factor associated with the primary endpoint of postoperative bleeding events. The secondary endpoint of whether or not patients received WF therapy was largely unrelated to bleeding events, all-cause mortality, and postoperative stroke up to 90 days after surgery.

CONCLUSIONS

Preliminary studies suggest that low body weight is a risk factor for postoperative bleeding events in patients on dialysis, although further exploration of other factors will be necessary with the accumulation of similar cases.

摘要

背景

透析患者的围手术期管理对于控制出血和血栓形成风险以及控制感染至关重要。术后抗凝往往难以控制,不同机构有不同的政策。因此,在本研究中,我们旨在调查与术后出血事件相关的因素,以及华法林(WF)治疗是否会影响术后出血事件的发生率、总死亡率和中风发生率。

方法

纳入心血管外科收治并接受瓣膜置换或成形术的患者,排除接受机械瓣膜植入的患者。本研究共纳入39例患者。主要终点是确定与术后出血事件复合终点相关的因素,次要终点是确定WF治疗对术后出血事件、全因死亡率和中风的效应大小以及交叉终点之间的关联强度。检查交叉项目之间的关联强度。

结果

低体重(p = 0.038)被确定为与术后出血事件主要终点相关的因素。患者是否接受WF治疗的次要终点在很大程度上与术后90天内的出血事件、全因死亡率和中风无关。

结论

初步研究表明,低体重是透析患者术后出血事件的危险因素,尽管随着类似病例的积累,有必要进一步探索其他因素。